Cardiac Biomarkers in the Identification of Future Risk in Chronic Obstructive Pulmonary Disease

Author(s): Kathleen Jahn, Eleni Papakonstantinou, Daiana Stolz

Journal Name: Current Topics in Medicinal Chemistry

Volume 16 , Issue 14 , 2016

Become EABM
Become Reviewer
Call for Editor

Graphical Abstract:


Chronic obstructive pulmonary disease (COPD) is a common and disabling disease and the third leading cause of global mortality behind ischemic heart disease and stroke. Acute exacerbations of COPD accelerate lung function decline affecting the quality of life of COPD patients and moreover, remain the major contributors to morbidity and mortality of these patients. Cardiovascular comorbidities are prevalent in COPD patients and of great importance since they have a negative impact on patients’ health status. During the past few years there is an increasing interest in potential molecules that can be measured accurately and reproducibly and that can be used in COPD as biomarkers to predict clinical important outcomes such as exacerbations, hospitalizations and mortality. Such molecules have been successfully used in cardiovascular diseases and therefore, cardiac biomarkers have attracted attention for their potential use in COPD. The present review summarizes the available evidence for the use of the most important cardiac biomarkers in the evaluation of COPD severity, outcomes and management.

Keywords: Cardiac biomarkers, Chronic obstructive pulmonary disease, Acute exacerbations of chronic obstructive pulmonary disease, Comorbidities, Copeptin, B-natriuretic peptide, Adrenomedullin, Troponin T.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2016
Published on: 30 September, 2015
Page: [1539 - 1549]
Pages: 11
DOI: 10.2174/1568026616666150930120233
Price: $65

Article Metrics

PDF: 39